Massive study to map Real-World GEP-NET care
NCT ID NCT07635316
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe current care patterns and survival, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
RECRUITINGEast Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Could a liver artery shot make cancer treatment more effective?
- Double PET scan may unlock secrets of gut tumors
- New registry tracks PRRT outcomes for neuroendocrine cancer patients
- Promising drug combo shows hope for slowing rare gut tumors